NVN | Jotup

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

Retrieved on:

Wednesday, October 11, 2023

Patent, ElectroCore, ECOR, United States Patent and Trademark Office, NVN, Pharmaceutical industry

U.S. Patent No.

Key Points:

U.S. Patent No.
11,779,756 entitled “Systems and Methods for Vagal Nerve Stimulation” was issued on October 10, 2023, and is generally related to a preferable treatment paradigm for nVNS that involves applying a single dose of stimulation for about 90 seconds to about 150 seconds, 2-4 times during a 24-hour period.
“Our intellectual property portfolio continues to grow,” stated Dan Goldberger, Chief Executive Officer of electroCore.
“This new patent strengthens our position around the application of non-invasive vagus nerve stimulation, and how frequently nVNS may be used by a patient or customer looking for relief.”

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

Retrieved on:

Tuesday, October 10, 2023

Stroke, ElectroCore, ECOR, Northwell Health, Abstract, Research, NVN, Pharmaceutical industry

ROCKAWAY, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.

Key Points:

Our data suggests that nVNS is safe and effective in reducing pain and potentially the use of other acute pain medications, including opioids in the immediate aftermath of a SAH.
NOVIS is a prospective randomized clinical trial with blinded outcome assessment being conducted at the Leiden University Medical Center (Leiden, The Netherlands).
150 patients with ischemic stroke are being randomly allocated (1:1) to nVNS for five days in addition to standard treatment versus standard treatment alone.
The strong mechanistic rational for nVNS as a potentially neuroprotective and anti-inflammatory treatment for acute neurological injury is further supported by this data showing the continued efficacy of nVNS for the treatment of pain.

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

Retrieved on:

Tuesday, September 26, 2023

United States Patent and Trademark Office, 1836 U.S. Patent Office fire, Seizure, Patent, ECOR, ElectroCore, NVN, Use, 3D printing, Medical device

ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.

Key Points:

ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.
U.S. Patent No.
“We continue to broaden our intellectual property portfolio and strengthen our position around systems utilizing mobile devices to control stimulators,” stated Dan Goldberger, Chief Executive Officer of electroCore.
“The addition of this new patent is an example of how electroCore’s nVNS technology may be expanded in the future to cover neurological and psychiatric conditions, and how our robust patent portfolio covering the use of mobile devices to operate a nerve stimulator may be leveraged in our new suite of products and devices.”

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

Retrieved on:

Tuesday, July 25, 2023

PTSD is an extreme mental health condition associated with changes in multiple neurophysiological systems such as inflammation and the autonomic nervous system and contributing to deficits in memory.

Key Points:

PTSD is an extreme mental health condition associated with changes in multiple neurophysiological systems such as inflammation and the autonomic nervous system and contributing to deficits in memory.
Many patients have limited or no response to currently available treatments for PTSD symptoms and associated cognitive dysfunction.
Vagus Nerve Stimulation (VNS) has been shown in preliminary studies to enhance function when paired with cognitive and motor tasks.
The study concluded the active group developed better attention and recall of paragraphs encoded with stimulation as well as for working memory tasks as compared to sham.

National Veterans Network Awarded Japanese American Confinement Sites Grant For Nisei Soldier Traveling Exhibition

Retrieved on:

Tuesday, June 27, 2023

WASHINGTON, June 27, 2023 /PRNewswire/ -- The National Veterans Network (NVN) has been awarded a $348,867 grant from the Department of Interior National Park Service Japanese American Confinement Sites (NPS JACS) grant program that will help fund the "I Am An American: the Nisei Soldier Experience," an 11-city traveling exhibition about the Japanese American World War II soldiers.

Key Points:

NVN and National Museum of U.S. Army to develop 11-city traveling exhibition
WASHINGTON, June 27, 2023 /PRNewswire/ -- The National Veterans Network (NVN) has been awarded a $348,867 grant from the Department of Interior National Park Service Japanese American Confinement Sites (NPS JACS) grant program that will help fund the "I Am An American: the Nisei Soldier Experience," an 11-city traveling exhibition about the Japanese American World War II soldiers.
The grant will enable the NVN, AHF and the Museum to begin working on the content and overall design of the traveling exhibition.
The National Veterans Network and the Army Historical Foundation will launch a national fundraising campaign this year to raise the remaining funds for the traveling exhibit.
For questions regarding the JACS grant program, please contact Kara Miyagishima, Program Manager, Japanese American Confinement Sites Grant Program, NPS, at 303-969-2885.

electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting

Retrieved on:

Tuesday, June 13, 2023

SUNA, ECOR, Poster, Headache, NVN, Jesse Russell, Patient, Trigeminal autonomic cephalgia, ElectroCore, Rare-earth element, Pharmaceutical industry

ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.

Key Points:

ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.
The abstract and poster highlight the observed efficacy of nVNS in three patients with rare headache diseases, SUNCT/SUNA, in the class of headache disorders known as Trigeminal Autonomic Cephalalgia’s (“TACs”).
The retrospective study suggests that nVNS, as a treatment for TACs in general, and specifically for refractory SUNCT/ SUNA, should be considered before microvascular neurosurgery, particularly given the well-recognized risks and costs of such surgical procedures.

Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning

Retrieved on:

Monday, April 24, 2023

Learning, TNT, DARPA, Air Force Research Laboratory, Nerve conduction study, Language, AFRL, ECOR, Student, NVN, Acquisition, DLI, Defense Language Institute, Atmosphere of Earth, ElectroCore, Management

The study was conducted at the Defense Language Institute (DLI) in Monterey, CA, the US Department of Defense’s premier language school.

Key Points:

The study was conducted at the Defense Language Institute (DLI) in Monterey, CA, the US Department of Defense’s premier language school.
The study was supported by Defense Advanced Research Projects Agency (DARPA)/AFRL within the DARPA Targeted Neuroplasticity Training (TNT) program.
The study recruited 36 student participants from DLI’s Arabic school house (nVNS = 18 & Sham = 18).
On days 2-4, two 2-minute gammaCore (nVNS) stimulation treatments were self-administered by the subject, each before and after training.

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

Retrieved on:

Wednesday, April 12, 2023

Patent, Vagus nerve, United States Patent and Trademark Office, United States patent law, Brain, Dopamine, Disorder, ECOR, US, NVN, ElectroCore, Addiction, Hertz, FDA, Pharmaceutical industry

ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points:

ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
The three patents were issued on April 11, 2023, and relate to the electroCore’s non-invasive vagus nerve stimulation (nVNS) technology, including the following patents:
US Patent Nos.
11,623,079 and 11,623,080 entitled “Vagal Nerve Stimulation Devices and Methods for Treating Medical Conditions” and “Vagal Nerve Stimulation for Dopamine-Related Conditions,” respectively.
“electroCore continues to broaden its intellectual property portfolio, which consists of over 200 patents and patent applications,” stated Dan Goldberger, Chief Executive Officer of electroCore.

electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan

Retrieved on:

Tuesday, April 11, 2023

Information technology, Medicines and Healthcare products Regulatory Agency, Sale, Medication, Pharmaceuticals and Medical Devices Agency, ECOR, Headache, NVN, PMDA, Health, FDA, Pharmaceutical industry, Lease, Teijin

Under the license agreement, the Company received a non-refundable, upfront payment for the licenses and rights granted to Teijin.

Key Points:

Under the license agreement, the Company received a non-refundable, upfront payment for the licenses and rights granted to Teijin.
Teijin’s exclusive rights are subject to a license fee payable on each anniversary of the license agreement until the first commercial sale in Japan on any approved indication.
By making the annual license fee payment, Teijin has extended its exclusive rights for another year.
As part of the license agreement, Teijin will have the right of first negotiation for a license to additional indications in Japan.

electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

Retrieved on:

Thursday, April 6, 2023

Nerve conduction study, ECOR, NVN, Patient, ElectroCore, SVP, Headache, Global Sales Law Project, Pharmaceutical industry, Far East

ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator (nVNS) in Indonesia.

Key Points:

ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator (nVNS) in Indonesia.
This follows the equivalent license approvals received in Malaysia in September 2022 and in South Africa in March 2023.
“Gaining wider global approvals and opening supply routes for gammaCore further validates the clinical evidence portfolio we have behind our technology, and more importantly, broadens the geographical access for patients and clinicians,” said Iain Strickland, SVP, Global Sales and Strategy at electroCore.
“The product registration in Indonesia, South Africa and Malaysia represent the first registrations we have in both the Far East and the African continent.”
Mr. Strickland continued, “It’s an exciting time to be building new clinician networks and we look forward to supporting our distributors Kromax South Asia and Byond Healthcare as they launch in their respective territories.